The Nitrosamine “Saga”: Lessons Learned from Five Years of ScrutinyRaphael Nudelman, Anne-Laure Werner, Stéphanie Simon et al.|Organic Process Research & Development|2023Cited by 78
N-Nitrosamine drug substance related impurities (NDSRIs) – A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel P. Bercu, Mike W Urquhart, Robert A. Jolly et al.|Regulatory Toxicology and Pharmacology|2024Cited by 14
Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakesDavid J. Ponting, Robert Thomas, Susanne Glowienke et al.|Regulatory Toxicology and Pharmacology|2024Cited by 13